Interventional studies are needed to determine whether it would be beneficial to provide additional treatments like inhibitors of sodium-glucose co-transporter-2 (SGLT2), along with lipid-lowering medications, to those with high AIP and CRI-II, since empagliflozine has been demonstrated to enhance diastolic function in a genetic model of T2DM ob/ob mice [61]. Here, SLC5A2 is linked to type 2 diabetes mellitus.